[go: up one dir, main page]

EP1173429A1 - Inhibiteurs de protease - Google Patents

Inhibiteurs de protease

Info

Publication number
EP1173429A1
EP1173429A1 EP00920078A EP00920078A EP1173429A1 EP 1173429 A1 EP1173429 A1 EP 1173429A1 EP 00920078 A EP00920078 A EP 00920078A EP 00920078 A EP00920078 A EP 00920078A EP 1173429 A1 EP1173429 A1 EP 1173429A1
Authority
EP
European Patent Office
Prior art keywords
group
disease
compound according
lkyl
galkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00920078A
Other languages
German (de)
English (en)
Other versions
EP1173429A4 (fr
Inventor
Dennis S. Yamashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1173429A1 publication Critical patent/EP1173429A1/fr
Publication of EP1173429A4 publication Critical patent/EP1173429A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/12—Eight-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • this invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to Formula I and a pharmaceutically acceptable carrier, diluent or excipient.
  • the compound of Formula I of this invention is a compound of Formula

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des inhibiteurs de protéase 4-amino-4,5-dihydro-benzo[b][1,4] dioxocin-3-one, et des sels pharmaceutiquement acceptables, leurs hydrates et leurs solvates inhibiteurs de protéase, comprenant de la cathépsine K, les compositions pharmaceutiques de ces composés. L'invention concerne également des procédés de traitement des maladies de perte osseuse excessive ou de dégénérescence de cartilage ou de la matrice, y compris l'ostéoporose; la maladie gingivale y compris la gingivite et la paradontite; l'arthrite, plus particulièrement, ostéoarthrite et la polyarthrite rhumatoïde; la maladie de Paget; l'hypercalcémie paranéoplasique; et la maladie métabolique des os, comportant l'inhibition de ladite perte osseuse excessive ou la dégénérescence excessive du cartilage ou de la matrice par l'administration à un patient qui en a besoin un composé de la présente invention.
EP00920078A 1999-03-31 2000-03-31 Inhibiteurs de protease Withdrawn EP1173429A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12725099P 1999-03-31 1999-03-31
US127250P 1999-03-31
PCT/US2000/008833 WO2000058296A1 (fr) 1999-03-31 2000-03-31 Inhibiteurs de protease

Publications (2)

Publication Number Publication Date
EP1173429A1 true EP1173429A1 (fr) 2002-01-23
EP1173429A4 EP1173429A4 (fr) 2002-06-19

Family

ID=22429122

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00920078A Withdrawn EP1173429A4 (fr) 1999-03-31 2000-03-31 Inhibiteurs de protease

Country Status (8)

Country Link
EP (1) EP1173429A4 (fr)
JP (1) JP2002540199A (fr)
AU (1) AU4066900A (fr)
CO (1) CO5180536A1 (fr)
HK (1) HK1044758A1 (fr)
PE (1) PE20001607A1 (fr)
UY (1) UY26088A1 (fr)
WO (1) WO2000058296A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (fr) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Inhibiteurs de protease
JP2003513924A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
NZ520588A (en) 2000-03-21 2004-06-25 Smithkline Beecham Corp Protease inhibitors
US7282512B2 (en) 2002-01-17 2007-10-16 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
JP2004196696A (ja) * 2002-12-18 2004-07-15 Kyowa Hakko Kogyo Co Ltd 関節炎の予防剤または治療剤
CN113651795B (zh) * 2021-09-14 2022-09-02 江西开源香料有限公司 一种西瓜酮的合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use

Also Published As

Publication number Publication date
JP2002540199A (ja) 2002-11-26
EP1173429A4 (fr) 2002-06-19
UY26088A1 (es) 2000-10-31
HK1044758A1 (zh) 2002-11-01
WO2000058296A1 (fr) 2000-10-05
PE20001607A1 (es) 2001-03-07
AU4066900A (en) 2000-10-16
CO5180536A1 (es) 2002-07-30

Similar Documents

Publication Publication Date Title
WO1998008802A1 (fr) Inhibiteurs de cysteine protease
AU2001243441A1 (en) Protease inhibitors
EP1307203A1 (fr) Inhibiteur de proteinase
NZ337889A (en) Cysteine Protease inhibitors of the Papain superfamily comprising cathepsin K protease inhibitors
EP1079821A1 (fr) Inhibiteurs de la protease
WO2000058296A1 (fr) Inhibiteurs de protease
WO2000029408A1 (fr) Inhibiteurs de morpholino-ethoxybenzofuran protease
WO2000049011A1 (fr) Inhibiteurs de protease
JP2003513956A (ja) プロテアーゼ阻害剤
EP1140897A1 (fr) Inhibiteurs de proteases
EP1161237A1 (fr) Inhibiteurs de protease
JP2003513926A (ja) プロテアーゼ阻害剤
US20040157828A1 (en) Protease inhibitors
WO2001034160A1 (fr) Inhibiteurs de protease
US20050256100A1 (en) Protease inhibitors
US20020165222A1 (en) Protease inhibitors
EP1384713B1 (fr) Derives de 4-amino-azepan-3-one comme inhibiteurs de protease
HUP0301964A2 (en) Protease inhibitors
US20020013360A1 (en) Protease inhibitors
US20050203084A1 (en) Protease inhibitors
US7109233B2 (en) Protease inhibitors
US20050256105A1 (en) Protease inhibitors
EP1511492A2 (fr) Inhibiteurs de protease
MXPA99010254A (en) Protease inhibitors
CZ388799A3 (cs) Inhibitory proteasy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010914

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 295/092 A, 7C 07D 321/12 B, 7C 07D 453/02 B, 7C 07D 327/00 B, 7C 07D 327/02 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020507

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020802

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1044758

Country of ref document: HK